Categories: NewsPharmaceutical

GUERBET : Financial agenda for 2026

Financial agenda for 2026

Villepinte, November 19, 2025: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is announcing its financial agenda for 2026.

Publications calendar
  • 2025 ANNUAL REVENUE

February 05, 2026, after trading

  • 2025 ANNUAL RESULTS

March 11, 2026, after trading

  • 2026 1ST QUARTER REVENUE

April 23, 2026, after trading

  • ANNUAL SHAREHOLDERS’ MEETING

May 22, 2026

  • 2026 2ND QUARTER REVENUE

July 23, 2026, after trading

  • 2026 FIRST HALF RESULTS

September 15, 2026, after trading

  • 2026 3RD QUARTER REVENUE

October 22, 2026, after trading

About Guerbet

At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a global leader in medical imaging, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. As pioneers in contrast products for 98 years, with more than 2,905 employees worldwide, we continuously innovate and devote 9% of our revenue to Research and Development in four centers in France and the United States. Guerbet (GBT) is listed in compartment B of Euronext Paris and generated revenue of €841m in 2024. For more information, please visit www.guerbet.com.

Contacts:

Guerbet     
Christine Allard, SVP Public Affairs and Corporate Communications +33 6 30 11 57 82 / christine.allard@guerbet.com

Seitosei.Actifin                                                                                       
Marianne Py, Financial Communication + 33 6 85 52 76 93 / marianne.py@seitosei-actifin.com
Anne-Claire Taton, Press +33 6 02 12 25 18 / anne-claire.taton@seitosei-actifin.com

Attachment

Staff

Recent Posts

Atropos Health Expands Oncology Precision Medicine Capabilities with Publication of New AI Algorithms for Rare Disease and Integration of ASCO Guidelines

Atropos Health is integrating the American Society of Clinical Oncology® (ASCO®) Guidelines into their platform…

5 hours ago

USF and Old Dominion to Play in the 2025 StaffDNA Cure Bowl

PLANO, Texas, Dec. 5, 2025 /PRNewswire/ -- Teams playing in the StaffDNA® Cure Bowl were…

5 hours ago

The Dot Corp Expands Services With New Promotional Products & Apparel Division

IRVINE, Calif., Dec. 5, 2025 /PRNewswire/ -- The Dot Corp has expanded its services with…

5 hours ago

Vaniam Group Launches Predictive Pathways: A New Capability for Anticipating Market-Shaping Signals

CHICAGO, Dec. 5, 2025 /PRNewswire/ -- Vaniam Group™, a category leader redefining medical communications, announced…

5 hours ago

Biorep Technologies Announces First Successful Independent Research Use of the PRISM System in Islet Isolation

Results confirm reproducibility and research readiness for islet isolation of Biorep's next generation laboratory platform.MIAMI,…

5 hours ago